123 related articles for article (PubMed ID: 18270995)
1. Sequence-based identification of specific drug target regions in the thymidylate synthase enzyme family.
Ferrari S; Losasso V; Costi MP
ChemMedChem; 2008 Mar; 3(3):392-401. PubMed ID: 18270995
[No Abstract] [Full Text] [Related]
2. Thymidylate synthase inhibitors.
Ismail AS; Grem JL
Cancer Chemother Biol Response Modif; 2001; 19():1-19. PubMed ID: 11686010
[No Abstract] [Full Text] [Related]
3. Design, synthesis and evaluation of potent thymidylate synthase X inhibitors.
Esra Onen F; Boum Y; Jacquement C; Spanedda MV; Jaber N; Scherman D; Myllykallio H; Herscovici J
Bioorg Med Chem Lett; 2008 Jun; 18(12):3628-31. PubMed ID: 18513963
[TBL] [Abstract][Full Text] [Related]
4. Contributions of protein structure-based drug design to cancer chemotherapy.
Jackson RC
Semin Oncol; 1997 Apr; 24(2):164-72. PubMed ID: 9129687
[TBL] [Abstract][Full Text] [Related]
5. On the use of PIPSA to guide target-selective drug design.
Henrich S; Richter S; Wade RC
ChemMedChem; 2008 Mar; 3(3):413-7. PubMed ID: 18061917
[No Abstract] [Full Text] [Related]
6. Design and synthesis of multisubstrate analog inhibitors of one-carbon transfer reactions.
Broom AD
Fed Proc; 1986 Nov; 45(12):2779-83. PubMed ID: 3533643
[TBL] [Abstract][Full Text] [Related]
7. [Inhibition of thymidylate synthase in chemotherapy].
Rode W
Postepy Biochem; 1996; 42(2):133-40. PubMed ID: 8805186
[No Abstract] [Full Text] [Related]
8. Prized malaria drug target nailed.
Rathod PK; Phillips MA
Nat Struct Biol; 2003 May; 10(5):316-8. PubMed ID: 12714998
[No Abstract] [Full Text] [Related]
9. [Enzymes as starting points for pharmaceutical development].
Wagner G
Pharmazie; 1984 Mar; 39(3):190-4. PubMed ID: 6728894
[No Abstract] [Full Text] [Related]
10. Pharmacological and toxicological evaluation of a new series of thymidylate synthase inhibitors as anticancer agents.
Benassi L; Magnoni C; Giudice S; Bertazzoni G; Costi MP; Rinaldi M; Venturelli A; Coppi A; Rossi T
Anticancer Res; 2006; 26(5A):3499-504. PubMed ID: 17094473
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase inhibitors.
Takimoto CH; Diggikar S
Cancer Chemother Biol Response Modif; 2005; 22():1-18. PubMed ID: 16110605
[No Abstract] [Full Text] [Related]
12. Thymidyl biosynthesis enzymes as antibiotic targets.
Chernyshev A; Fleischmann T; Kohen A
Appl Microbiol Biotechnol; 2007 Feb; 74(2):282-9. PubMed ID: 17216455
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase inhibitors.
Ackland SP; Clarke SJ; Beale P; Peters GJ
Cancer Chemother Biol Response Modif; 2002; 20():1-36. PubMed ID: 12703198
[No Abstract] [Full Text] [Related]
14. Thymidylate synthase as a chemotherapeutic drug target: where are we after fifty years?
Berger FG; Berger SH
Cancer Biol Ther; 2006 Sep; 5(9):1238-41. PubMed ID: 17035726
[No Abstract] [Full Text] [Related]
15. [Advance in researches of drugs derived from marine bacteria].
Lin BX; Huang ZQ; Xie LH
Wei Sheng Wu Xue Bao; 2005 Aug; 45(4):657-60. PubMed ID: 16245893
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor specificity via protein dynamics: insights from the design of antibacterial agents targeted against thymidylate synthase.
Ferrari S; Costi PM; Wade RC
Chem Biol; 2003 Dec; 10(12):1183-93. PubMed ID: 14700626
[TBL] [Abstract][Full Text] [Related]
17. Bacterial beta-ketoacyl-acyl carrier protein synthase III (FabH): an attractive target for the design of new broad-spectrum antimicrobial agents.
Castillo YP; Pérez MA
Mini Rev Med Chem; 2008 Jan; 8(1):36-45. PubMed ID: 18220983
[TBL] [Abstract][Full Text] [Related]
18. Hotspots in an obligate homodimeric anticancer target. Structural and functional effects of interfacial mutations in human thymidylate synthase.
Salo-Ahen OM; Tochowicz A; Pozzi C; Cardinale D; Ferrari S; Boum Y; Mangani S; Stroud RM; Saxena P; Myllykallio H; Costi MP; Ponterini G; Wade RC
J Med Chem; 2015 Apr; 58(8):3572-81. PubMed ID: 25798950
[TBL] [Abstract][Full Text] [Related]
19. N4-hydroxy-5-halogeno-2'-deoxycytidine S and their 5'-mono-phosphates as inhibitors of thymidylate synthase and in vitro antileukemic agents.
Felczak K; Bretner M; Dzik JM; Gołos B; Zieliński Z; Rode W; Kulikowski T
Adv Exp Med Biol; 1998; 431():617-21. PubMed ID: 9598139
[No Abstract] [Full Text] [Related]
20. Alanine mutants of the interface residues of human thymidylate synthase decode key features of the binding mode of allosteric anticancer peptides.
Tochowicz A; Santucci M; Saxena P; Guaitoli G; Trande M; Finer-Moore J; Stroud RM; Costi MP
J Med Chem; 2015 Jan; 58(2):1012-8. PubMed ID: 25427005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
